May 2023

NEWS & COLUMNS

6-7 NEWS
Merck to acquire Prometheus Biosciences for almost $11bn; Astellas to acquire Iveric Bio for $5.9bn

8-9 NEWS
J&J offers almost $9bn to end talc lawsuits; Biogen given FDA accelerated approval for ALS drug

10 CORONAVIRUS NEWS
WHO declares end of COVID-19 global emergency

11 DERMATOLOGY NEWS
Almirall dermatology study first to assess well-being

12 DARWIN'S MEDICINE
Adapting to market changes

13 POLICY AND PUBLIC HEALTH
Generative AI is coming for healthcare

14 ALWAYS ONE MORE THING TO LEARN
Why continued learning is essential

15 INNOVATIVE IMPACT BLOG
The omnichannel conundrum

FEATURES

16-17 TUBERCULOSIS – WHY IT REMAINS A MAJOR GLOBAL PUBLIC HEALTH CHALLENGE
Despite several new TB medicines and treatment regimens being introduced in recent years after more than 40 years of no new treatment options, successfully treating TB remains complex and challenging. Innovative collaboration is required to address the major public health challenges around TB and expedite drug development

20-22 WORLD CONGRESS ON CONTROVERSIES IN NEUROLOGY
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women. Attending the congress in Dubrovnik, Croatia were four patients who were there to tell their stories.

24-25 PARKINSON’S DISEASE: PAST, PRESENT AND FUTURE
Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders in the world that affects over 10 million people 

20. World Congress on Controversies in Neurology